2022 ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸ : 2022-10-07±³À°ÀÏÀÚ : 2022-10-07
±³À°Àå¼Ò : °Ç±¹´ëÇб³ »õõ³â°ü ´ë°ø¿¬Àå
±³À°ÁÖÁ¦ :
2022 ´ëÇѹé½ÅÇÐȸ Ãß°èÇмú´ëȸÁÖÃÖ±â°ü : ´ëÇѹé½ÅÇÐȸ
´ã´çÀÚ : Á¤ÇýÀ±
¿¬¶ôó : 02-2626-1099
À̸ÞÀÏ :
office@korvac.org ±³À°Á¾·ù : ³»°ú, ¼Ò¾Æû¼Ò³â°ú, »êºÎÀΰú, À̺ñÀÎÈÄ°ú, °¡Á¤ÀÇÇаú¿¹¹æÀÇÇÐ, ºÐÀÚ»ý¹°ÇÐ, ¹Ì»ý¹°ÇÐ
Âü¼®¿¹»óÀοø : 300¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 6 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 100,000¿ø
ºñ°í ȸ¿ø1)Àü¹®ÀÇ,¹Ú»ç±Þ ÀÌ»ó ¼±ÀÓ ¹× Ã¥ÀÓ¿¬±¸ÀÚ: »çÀüµî·Ï5¸¸¿ø.Ãß°¡µî·Ï7¸¸¿ø 2)Àü°øÀÇ,´ëÇлý ¹× ¼®»ç±Þ ÀÌÇÏ ¿¬±¸¿ø: »çÀüµî·Ï3¸¸¿ø/Ãß°¡µî·Ï5¸¸¿øºñȸ¿ø »çÀüµî·Ï 8¸¸¿ø/Ãß°¡µî·Ï10¸¸¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 09:00~09:20 Strategy for the Selection of Universal Vaccine Antigen ±è±â¼ø(°í·Á´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 09:20~09:40 biodegradible microneedle system for vaccine-delivery Á¤ÇüÀÏ(¿¬¼¼´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 09:40~10:00 Modulation of dendritic cells inducing better outcome of host protection À±Ã¶Èñ(¼¿ï´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 10:00~10:50 Coronavirus discovery – phylogeny and interspecies jumping Patrick CY WOO(Hongkong University)
ÈÞ½Ä 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 10:50~11:00 Coffee Break ()
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 11:00~11:20 Attenuation of influenza virus based on partial truncation of non-strutural gene for developing vaccine candidate ³ª¿î¼º(Àü³²´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 11:20~11:40 Swine hepatitis E virus vaccine ÃÖâ¼ø(Áß¾Ó´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 11:40~12:00 Development status and strategy of monkeypox vaccine ȲÀ±È£(Áúº´°ü¸®Ã»)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 12:00~12:20 The current status of new tuberculosis vaccine development Á¤Çý¼÷(Áúº´°ü¸®Ã»)
±âŸ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 12:20~12:40 ´ëÇѹé½ÅÇÐȸ ÃÑȸ ()
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 12:40~13:00 Æ÷½ºÆ®-Äڷγª19 ´ëºñ °¨¿°º´ ¹é½Å ¿¬±¸ °³¹ß Áö¿ø Àü·« ÀÌÀ¯°æ(Áúº´°ü¸®Ã»)
½Ä»ç 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 13:00~14:00 Á¡½É½Ä»ç ()
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 14:00~14:20 RSV: recent epidemiology and advances in mAb/vaccine development À±±â¿í(¼¿ï´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 14:20~14:40 Pneumococcal infection and vaccine in children and adults: recent updates ÀÌÁرâ(ÃæºÏ´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 14:40~15:00 chickenpox (varicella) and shingles (herpes zoster) vaccines: an update ¾ÈÁ¾±Õ(¿¬¼¼´ëÇб³)
±³À°½Ã°£ 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 15:00~15:30 The process and experience in the development and approval of a COVID-19 (GBP-510) vaccine ¼ÛÁØ¿µ(°í·Á´ëÇб³)
Åä·Ð 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 15:30~16:00 Panel discussion Real experience and lessons COVID-19 vaccine development ()
ÈÞ½Ä 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 16:00~16:10 Coffee Break ()
Åä·Ð 10-07 °Ç±¹´ëÇб³»õõ³â°ü´ë°ø¿¬Àå 16:10~17:00 poster presentaton ()